E O Reiter

Summary

Affiliation: Baystate Medical Center
Country: USA

Publications

  1. ncbi request reprint The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency
    Edward O Reiter
    Baystate Medical Center Children s Hospital, Tufts University School of Medicine Springfield, MA 01199, USA
    Horm Res 60:68-73. 2003
  2. ncbi request reprint A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from America
    Edward O Reiter
    Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
    Mol Cell Endocrinol 254:221-5. 2006
  3. ncbi request reprint Testotoxicosis: current viewpoint
    Edward O Reiter
    Department of Pediatrics, Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
    Pediatr Endocrinol Rev 3:77-86. 2005
  4. pmc Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder
    Paul Saenger
    Albert Einstein College of Medicine, Winthrop University Hospital, 120 Mineola Boulevard, Mineola, NY, 13501, USA
    Int J Pediatr Endocrinol 2012:12. 2012
  5. ncbi request reprint Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT)
    Edward O Reiter
    Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA, USA
    J Pediatr Endocrinol Metab 23:999-1009. 2010
  6. ncbi request reprint Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database
    Edward O Reiter
    Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, Massachusetts 01199, USA
    J Clin Endocrinol Metab 91:2047-54. 2006
  7. ncbi request reprint Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner's syndrome
    E O Reiter
    Departments of Pediatrics, Baystate Medical Center Children s Hospital and Tufts University School of Medicine, Springfield, Massachusetts 01199, USA
    J Clin Endocrinol Metab 86:1936-41. 2001
  8. ncbi request reprint A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency
    E O Reiter
    Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
    J Clin Endocrinol Metab 86:4700-6. 2001
  9. ncbi request reprint Educated?... For uncertainty
    Edward O Reiter
    Department of Pediatrics, Tufts University School of Medicine, Baystate Medical Center Children s Hospital, Springfield, MA 01199, USA
    J Pediatr Endocrinol Metab 15:3-4. 2002
  10. ncbi request reprint A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency
    Bernard L Silverman
    Department of Pediatrics, Northwestern University, Chicago, IL, USA
    J Pediatr Endocrinol Metab 15:715-22. 2002

Detail Information

Publications29

  1. ncbi request reprint The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency
    Edward O Reiter
    Baystate Medical Center Children s Hospital, Tufts University School of Medicine Springfield, MA 01199, USA
    Horm Res 60:68-73. 2003
    ..These data suggest that the attainment of a substantial height SDS by manipulating the tempo of puberty is limited, but that optimizing growth during the pre-pubertal phase is a more important factor...
  2. ncbi request reprint A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from America
    Edward O Reiter
    Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
    Mol Cell Endocrinol 254:221-5. 2006
    ..No universally agreed guidelines exist for the use of GnRH-Ag plus GH in children with GHD or other short stature syndromes and may still be considered experimental...
  3. ncbi request reprint Testotoxicosis: current viewpoint
    Edward O Reiter
    Department of Pediatrics, Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
    Pediatr Endocrinol Rev 3:77-86. 2005
    ..These agents are well tolerated in the populations in which they have been studied and effectively inhibit testosterone activity and estrogen production, in adult patients...
  4. pmc Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder
    Paul Saenger
    Albert Einstein College of Medicine, Winthrop University Hospital, 120 Mineola Boulevard, Mineola, NY, 13501, USA
    Int J Pediatr Endocrinol 2012:12. 2012
    ..This article reviews the results of these studies and summarizes the success of hGH therapy in treating this difficult and genetically heterogenous disorder...
  5. ncbi request reprint Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT)
    Edward O Reiter
    Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA, USA
    J Pediatr Endocrinol Metab 23:999-1009. 2010
    ..To evaluate the efficacy, tolerability, and pharmacokinetics of bicalutamide plus anastrozole in young males with testotoxicosis...
  6. ncbi request reprint Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database
    Edward O Reiter
    Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, Massachusetts 01199, USA
    J Clin Endocrinol Metab 91:2047-54. 2006
    ..Although successful in increasing height velocity, such treatment often falls short of helping patients achieve full genetic height potential...
  7. ncbi request reprint Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner's syndrome
    E O Reiter
    Departments of Pediatrics, Baystate Medical Center Children s Hospital and Tufts University School of Medicine, Springfield, Massachusetts 01199, USA
    J Clin Endocrinol Metab 86:1936-41. 2001
    ..If GH therapy were started early, E treatment could be initiated at a younger, more age-appropriate time without compromising adult height...
  8. ncbi request reprint A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency
    E O Reiter
    Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
    J Clin Endocrinol Metab 86:4700-6. 2001
    ..Patients achieved similar growth velocities when sustained release GH was given once or twice monthly. The enhanced convenience of this dosage form may result in greater long-term adherence to the treatment regimen...
  9. ncbi request reprint Educated?... For uncertainty
    Edward O Reiter
    Department of Pediatrics, Tufts University School of Medicine, Baystate Medical Center Children s Hospital, Springfield, MA 01199, USA
    J Pediatr Endocrinol Metab 15:3-4. 2002
  10. ncbi request reprint A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency
    Bernard L Silverman
    Department of Pediatrics, Northwestern University, Chicago, IL, USA
    J Pediatr Endocrinol Metab 15:715-22. 2002
    ..c.) injection. The availability of this formulation offers the opportunity for greater convenience and compliance by decreasing the number of injections and frequency of administration required...
  11. ncbi request reprint Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome
    Holley F Allen
    Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
    J Pediatr Endocrinol Metab 18:761-8. 2005
    ..We evaluated the hypothesis that metformin would improve signs and symptoms of polycystic ovary syndrome (PCOS) in adolescents as compared to oral contraceptive pills (OCP) and have a favorable effect on obesity...
  12. ncbi request reprint Small for gestational age: short stature and beyond
    Paul Saenger
    Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York 10467, USA
    Endocr Rev 28:219-51. 2007
    ..Recent data, however, suggest that long-term treatment with GH does not increase the risk of type 2 diabetes mellitus and the metabolic syndrome in young adults born SGA...
  13. ncbi request reprint Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy
    Rubina A Heptulla
    Department of Pediatrics, Baylor College of Medicine, Texas Children s Hospital, Houston, TX 77030 2399, USA
    Pediatr Diabetes 5:10-5. 2004
    ..This study was undertaken to determine the specific areas of improved glycemic control in subjects after initiation of insulin pump therapy and times where further improvement is needed. Research..
  14. ncbi request reprint Delayed puberty
    Edward O Reiter
    Department of Pediatrics, Bayside Medical Center Children s Hospital, Tufts University School of Medicine, Sprinfield, Massachusetts 01199, USA
    Adolesc Med 13:101-18, vii. 2002
    ..Diagnostic assessment and varied therapeutic modalities are discussed. The issues of androgen or estrogen therapy are important to assess, and growth hormone treatment remains a difficult dilemma...
  15. ncbi request reprint HIV--associated lipodystrophy in children
    Jens C Krause
    Baystate Children s Hospital, Tufts University School of Medicine, Department of Pediatrics, 759 Chestnut Street, Springfield, MA 01199, USA
    Pediatr Endocrinol Rev 3:45-51. 2005
    ..GH resistance in LD needs to be better characterized. While some cytokines show promise as markers for LD, it is difficult to tell whether their derangement is a cause of or the effect of LD...
  16. ncbi request reprint Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database)
    Maria E Craig
    Institute of Endocrinology and Diabetes, Children s Hospital at Westmead, Westmead, NSW, Australia
    Clin Endocrinol (Oxf) 65:178-85. 2006
    ..To evaluate the response to recombinant GH treatment and adverse events in children with Prader-Willi syndrome (PWS) from KIGS, the Pfizer International Growth Database...
  17. ncbi request reprint Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial
    Erica A Eugster
    Pediatric Endocrinology, Riley Hospital for Children, Indiana Uniuversity School of Medicine, 702 Barnhill Drive, Indianapolis, IN 46202, USA
    J Clin Endocrinol Metab 92:1697-704. 2007
    ..GnRH analog (GnRHa) therapy for central precocious puberty (CPP) typically involves im injections. The histrelin implant is a new treatment that provides a continuous slow release of the GnRHa histrelin...
  18. ncbi request reprint Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature
    Michael B Ranke
    Paediatric Endocrinology Section, Children s Hospital, University of Tubingen, Tubingen, Germany
    Horm Res 68:53-62. 2007
    ..To develop methods to identify factors associated with a favorable outcome in GH-treated children with idiopathic short stature (ISS)...
  19. ncbi request reprint Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database)
    Michael B Ranke
    Sektion P├Ądiatrische Endokrinologie, Universitatsklinikum Tubingen, Eberhard Karls Universitat, D 72076 Tubingen, Germany
    J Clin Endocrinol Metab 88:125-31. 2003
    ..Furthermore, this model can be used to provide patients with a realistic expectation of treatment and may help to identify compliance problems or other underlying causes of treatment failure...
  20. ncbi request reprint Final height in children with medulloblastoma treated with growth hormone
    Michael B Ranke
    Paediatric Endocrinology Section, Children s Hospital, University of Tubingen, Tubingen, Germany
    Horm Res 64:28-34. 2005
    ..Height in general is severely compromised in survivors. The present study is an extension of the investigation by the author's group of the effect of exogenous growth hormone (GH) among medulloblastoma patients...
  21. ncbi request reprint The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose
    Michael B Ranke
    Pediatric Endocrinology Section, University Children s Hospital, Tubingen D 72076 Germany
    J Clin Endocrinol Metab 88:4748-53. 2003
    ..The use of a higher GH dosage at the onset of puberty should thus depend on the individual's height development. The TPG model aids in the planning of individually optimized and cost-effective GH treatment...
  22. ncbi request reprint Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS
    Michael B Ranke
    Pediatric Endocrinology Section, University Children s Hospital, Hoppe Seyler Strasse 1, D 72076 Tuebingen, Germany
    J Clin Endocrinol Metab 90:1966-71. 2005
    ..The early detection and GH treatment of congenital GHD is advantageous as a cost-effective strategy for achieving greater improvement of absolute height and growth velocity...
  23. ncbi request reprint Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data fr
    Feyza Darendeliler
    Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
    Horm Res 63:40-7. 2005
    ....
  24. ncbi request reprint Insulin-like growth factors as diagnostic tools in growth hormone deficiency during childhood and adolescence: the KIGS experience
    Michael B Ranke
    Paediatric Endocrinology Section, University Children s Hospital, Tubingen, Germany
    Horm Res 62:17-25. 2004
    ....
  25. ncbi request reprint Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS
    Michael B Ranke
    Paediatric Endocrinology Section, Children s Hospital, University of Tuebingen, D 72076 Tuebingen, Germany
    Pediatr Res 61:105-10. 2007
    ..Evidently, height at GH start (the taller, the better), age at GH start (the younger, the better), the responsiveness to GH (the higher, the better) and age at puberty (the later, the better) determine NAH...
  26. ncbi request reprint Work group I: developing models of healthy adolescent physical development
    Elizabeth J Susman
    The Pennsylvania State University, University Park, Pennsylvania 16802, USA
    J Adolesc Health 31:171-4. 2002
  27. ncbi request reprint A growth prediction model for short children born small for gestational age
    Michael B Ranke
    Paediatric Endocrinology Section, University Children s Hospital, Tubingen, Germany
    J Pediatr Endocrinol Metab 15:1273. 2002
  28. ncbi request reprint Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial
    Erica A Eugster
    James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Pediatr 143:60-6. 2003
    ..We undertook a 1-year multicenter trial of tamoxifen treatment for precocious puberty in girls with McCune-Albright syndrome (MAS)...
  29. ncbi request reprint Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial
    Paul V Plourde
    AstraZeneca Pharmaceuticals LP, Chesapeake 2B 126, 1800 Concord Pike, P O Box 15437, Wilmington, Delaware 19850 5437, USA
    J Clin Endocrinol Metab 89:4428-33. 2004
    ....